Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now X
ETFs with BIIB as a Top 10 Holding*
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|10%||iShares Nasdaq Biotechnology Index Fund (IBB)||+62.14 (22.57%)|
|8.35%||Market Vectors Biotech ETF (BBH)||+22.02 (20.78%)|
|6.34%||PowerShares Dynamic Biotech &Genome (PBE)||+8.20 (17.59%)|
|4.59%||Columbia Select Large Cap Growth ETF (RWG)||+1.53 (3.34%)|
|3.76%||First Trust Amex Biotech Index Fund (FBT)||+23.48 (25.59%)|
Company Description (as filed with the SEC)
Biogen Idec is a global biopharmaceutical company focused on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders. Our principal marketed products include AVONEX, PLEGRIDY, TECFIDERA, TYSABRI, and FAMPYRA for multiple sclerosis (MS), ALPROLIX for hemophilia B and ELOCTATE for hemophilia A. We also collaborate on the development and commercialization of RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA which is approved for the treatment of chronic lymphocytic leukemia. We are focused on discovering and developing new therapies that improve the lives of patients having diseases with high unmet medical needs. ... More ...
Where does BIIB fit in the risk graph?
|Annual EPS Est:||$13.79|
|Quarterly EPS Est:||3.96|